Saltar al contenido
Merck

Saltar a

1344702

USP

Iopamidol

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(S)-N,N′-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
Tamaño de envaseSKUDisponibilidadPrecio
200 mg
Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad
423,00 €

Acerca de este artículo

Fórmula empírica (notación de Hill):
C17H22I3N3O8
Número CAS:
Peso molecular:
777.09
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

423,00 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicite una orden a granel
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


grade

pharmaceutical primary standard

API family

iopamidol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Ic1c(c(c(c(c1C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)NC(=O)[C@@H](O)C

InChI

1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

InChI key

XQZXYNRDCRIARQ-LURJTMIESA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Iopamidol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Iopamidol Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
I03290001344724PHR1985
USP

USP

1344702

Iopamidol

vibrant-m

I0329000

Iopamidol

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

-

format

neat

format

neat

format

neat

format

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

API family

iopamidol

API family

iopamidol

API family

iopamidol

API family

-


Still not finding the right product?

Explore all of our products under


Clase de almacenamiento

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Katsuya Miura et al.
International journal of cardiology, 181, 108-113 (2014-12-17)
The slow flow (SF) phenomenon is more prevalent in patients with acute coronary syndrome (ACS), who frequently exhibit vulnerable plaques in remote coronary arteries. We aimed to clarify the impact of nonculprit plaque characteristics on the occurrence of SF using
Akira Sato et al.
International journal of cardiology, 182, 419-425 (2015-01-18)
Coronary plaques with positive remodeling (PR) and low-attenuation plaques (LAP) by computed tomography angiography (CTA) might be associated with plaque vulnerability. The purpose of this study was to assess the relation between coronary plaques with PR and LAP by CTA
Nobuo Tomizawa et al.
International journal of cardiology, 176(3), 975-979 (2014-09-07)
The purpose was to investigate the diagnostic performance of coronary computed tomography angiography (CTA) when non-calcified uninterpretable segments were determined as either obstructive or patent. We also investigated the factors that could improve the diagnosis of CTA. A total of



Número de artículo de comercio global

SKUGTIN
1344702-200MG04061838730107

Preguntas

Revisiones

Sin puntuación

Filtros activos